Zimmer Biomet Appoints New President and CEO

Zimmer Biomet Holdings, Inc. has announced a significant leadership change, with the appointment of Ivan Tornos as the new President and Chief Executive Officer (CEO) and his election to the Board of Directors. 

This change is effective immediately, and Tornos steps into this role after serving as Chief Operating Officer of Zimmer Biomet since early 2021. He succeeds Bryan Hanson, who has held the position of President and CEO since late 2017 and Chairman since 2021 but is now leaving to assume another CEO role.

Expanding Roles and Responsibilities

In addition to Ivan Tornos assuming the CEO role, Suketu (Suky) Upadhyay, who joined Zimmer Biomet as Executive Vice President (EVP) and Chief Financial Officer (CFO) in 2019, will expand his responsibilities. Upadhyay will now oversee the Company’s global Operations and Supply Chain functions in addition to his existing CFO role.

Christopher Begley, the current Lead Independent Director of Zimmer Biomet, will assume the role of Chairman of the Board, effective immediately. This leadership transition aims to ensure continuity and stability within the organisation.

ZimVie’s Exclusive Puros® Cancellous Particulate Allograft Dental Bone Grafting Solution Excels in Landmark Comparative Study

Reaffirming Financial Guidance

Zimmer Biomet has reaffirmed its full-year 2023 financial guidance as outlined in its second-quarter financial results, which were announced on August 1, 2023.

Ivan Tornos, the newly appointed CEO, expressed his enthusiasm for leading Zimmer Biomet during a period of remarkable growth and innovation. He praised Bryan Hanson’s leadership and transformational efforts within the company and stated his commitment to advancing the standard of musculoskeletal care.

A Distinguished Career

Tornos brings extensive experience to his new role, having joined Zimmer Biomet in November 2018 as Group President, Orthopaedics. He later assumed the position of Group President, Global Businesses and the Americas. In March 2021, he was appointed Chief Operating Officer, where he had oversight of global businesses, operations, clinical and medical education, as well as global research and development and new product development functions. His responsibilities spanned the Americas and the Europe, Middle East, and Africa (EMEA) regions.

Dental Biomaterials Market Set to Achieve $15.8 Billion by 2030

Bryan Hanson, who departs from Zimmer Biomet to become CEO of the healthcare spinoff of 3M, reflected on his transformative leadership during his tenure. He highlighted his confidence in Ivan Tornos’s ability to lead Zimmer Biomet into its next phase of innovation and growth.

About Zimmer Biomet

Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximise mobility and improve health. The company leverages innovative products and integrated digital and robotic technologies, including data analytics and artificial intelligence, to enhance the patient experience. With over 90 years of leadership and expertise, Zimmer Biomet continues to evolve and innovate, with a commitment to delivering the highest quality solutions to patients and providers.